Available Opportunities
Project Sierra
A pharmaceutical company established in 2016, serves as a manufacturer, distributor, and MAH with 5 branded products, OTC offerings, generic dossiers, and ongoing CDMO contracts across 19 countries, certification for capsules, tablets, semi-solids, suppositories, and injectables (new line under investment), while providing CMO/CDMO, out-licensing, QA/QC, warehousing, and cosmetic manufacturing services, achieving $7.7M net revenue but -$5.4M EBITDA due to heavy capex in the new injectables facility, and actively seeking acquisition or strategic investment.
Project Kilo
A compact CDMO and own-brand distributor with 15 employees, two manufacturing units for pharmaceuticals and food supplements, worldwide distribution through partners, $4.5M net revenue, and owners open to selling 70% stake (retaining 30%) or a full 100% exit.
Project Echo
A pharmaceutical company established in 1997, specializing in OTC products,
effervescent tablets, food supplements, medical devices, chewables, and ODTs, offers
contract manufacturing and private label services, with a 2022–2025 strategy focused on
expanding its own product range, strengthening commercial presence in CIS, EU, Baltic, and
Scandinavian markets, seeking partners for novel-technology drug development, and scaling
CMO services following recent investment in a new biotech facility, achieving €2M net
revenue but -€0.4M EBITDA in 2022 due to that capex.
Project Golf
A CDMO established in 2015, with ~400 employees and a single corporate owner,
offers high-capacity solid oral dosage production (4+ billion tablets/capsules annually),
packaging (80+ million units/year), full drug substance and drug product services including
fill & finish and analytical support via a major biotech facility investment since 2020, serves
international big pharma and generic clients with worldwide distribution, achieved €55M net
revenue in 2022, and is positioned for growth despite a temporary EBITDA impact from
recent heavy capital expenditure.
Project Juliett
A drug discovery CRO established in 2005, with 54 employees and a single owner,
specializes in immuno-oncology, immune-modulation, and lung diseases through integrated
services in drug discovery, in vivo pharmacology, medicinal chemistry, bioanalytics, and
formulation, serving major clients like GSK, and generating $3M net revenue with $0.26M
EBITDA in 2022.
Project Tango
A debt-free, privately owned pharmaceutical company established in 1987, with $70M revenue, 28% EBITDA, 58 branded generic RX products focused on oncology, hematology, rheumatology, orphan drugs, and rare diseases, multiple EU-GMP manufacturing sites, distribution in 40 countries, and an owner open to 100% acquisition.
Project Atlas
Project Atlas is an established U.S.-based Contract Development and Manufacturing Organization (CDMO) specializing in solid dose and small molecule drug products.
The company delivers end-to-end pharmaceutical services including:
Development
Manufacturing
Packaging
Operates under FDA-approved cGMP facilities.
Existing infrastructure and capabilities support expansion into additional dosage forms, including:
Other small molecules
Oral solutions
Topicals
Time-release formulations
Liposomal products
Project Firefly
Project Firefly is a US-established pharmaceutical company focused on high-value branded respiratory products.
The company maintains a truly global footprint with:
Manufacturing, R&D, and marketing operations in over 25 countries
Registered entities in the United States, United Kingdom, Ireland, India, and Australia
This investment opportunity is specifically for equity in the US company, enabling investors to participate directly in the fast-growing US respiratory market while leveraging the group’s established global infrastructure and supply chain.
Project Dynamo
US$40–60 million for 30%–49% equity stake
Partner with a proven, export-oriented specialty pharmaceutical company serving 200+ global pharma clients and positioned for high-growth in complex generics and innovative delivery systems.
Project Romeo
This opportunity offers a strategic buyer (regional pharma player, OTC/nutraceutical consolidator, or private equity investor) immediate entry into expanding consumer health, food supplements, and branded generics market — featuring high-margin branded assets, marketing-driven growth engine, loyal distribution, and a turnkey sales & regulatory platform for further expansion in Eastern Europe.
The combination of strong profitability, lean operations, and proven brand-building capability positions this as an attractive bolt-on or standalone platform at a compelling valuation.
Project Hotel
Virtual pharma company (est. 2006) owned by three physician-inventors, specializing in a well-branded portfolio of three innovative prenatal, postnatal, and gynecological food supplements and medical devices, generating $0.5M in revenue and $0.06M EBITDA through a lean distributor-based model.
The company is seeking a strategic investor, buyer, or commercialization partner to unlock international expansion and scale its proven, niche maternal-health offerings.